Non-Raft AC2 Defines a cAMP Signaling Compartment That Selectively Regulates IL-6 Expression in Airway Smooth Muscle Cells by Bogard, Amy S. et al.
Chapman University
Chapman University Digital Commons
Pharmacy Faculty Articles and Research School of Pharmacy
2014
Non-Raft AC2 Defines a cAMP Signaling
Compartment That Selectively Regulates IL-6







Follow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles
Part of the Amino Acids, Peptides, and Proteins Commons, Cell Biology Commons, and the
Other Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.
Recommended Citation
Amy S. Bogard, Anna V. Birg and Rennolds S Ostrom. Non-raft AC2 defines a cAMP signaling compartment that selectively regulates
IL-6 expression in airway smooth muscle cells. Naunyn-Schmiedebergs Arch Pharmacol, 387(4):329-39, 2014.
Non-Raft AC2 Defines a cAMP Signaling Compartment That Selectively
Regulates IL-6 Expression in Airway Smooth Muscle Cells
Comments
This article was originally published in Naunyn-Schmiedeberg's Archives of Pharmacology, volume 387, issue 4,
in 2014. DOI: 10.1007/s00210-013-0950-4




This article is available at Chapman University Digital Commons: https://digitalcommons.chapman.edu/pharmacy_articles/384
	   1	  
Non-­‐raft	  adenylyl	  cyclase	  2	  defines	  a	  cAMP	  signaling	  compartment	  that	  selectively	  
regulates	  IL-­‐6	  expression	  in	  airway	  smooth	  muscle	  cells:	  differential	  regulation	  of	  
gene	  expression	  by	  AC	  isoforms	  	  Amy	  S.	  Bogard,	  Anna	  V.	  Birg	  and	  Rennolds	  S	  Ostrom.	  	  Department	  of	  Pharmacology,	  University	  of	  Tennessee	  Health	  Science	  Center	  Memphis,	  TN	  38163	  	  Address	  correspondence	  to:	   Rennolds	  S	  Ostrom,	  Ph.D.	  	  	  	  	   Department	  of	  Pharmacology	  	   University	  of	  Tennessee	  Health	  Science	  Center	  	  	   874	  Union	  Ave.,	  Crowe	  115	  	   Memphis,	  TN	  38163	  	   (901)	  448-­‐1181	  	   FAX	  (901)	  448-­‐7206	  	   rostrom@uthsc.edu	  	  List	  of	  non-­‐standard	  abbreviations:	  	  AC,	  adenylyl	  cyclase;	  cAMP,	  cyclic	  3’,5’	  adenosine	  monophosphate;	  BSMC,	  bronchial	  smooth	  muscle	  cells;	  Fsk,	  forskolin;	  IL-­‐6,	  interleukin	  6;	  GPCR,	  G	  protein-­‐coupled	  receptor;	  Epac,	  exchange	  protein	  activated	  by	  cAMP;	  PKA,	  protein	  kinase	  A;	  AP-­‐1,	  activator	  protein	  1;	  CRE,	  cAMP	  response	  element;	  βAR,	  beta-­‐adrenergic	  receptor;	  PKC,	  protein	  kinase	  C;	  CaM,	  calmodulin;	  Iso,	  isoproterenol;	  NECA,	  5'-­‐N-­‐ethylcarboxamidoadenosine	  ;	  AVP,	  Arginine vasopressin; α-CGRP, α-calcitonin gene related 
peptide; PGD2, prostaglandin D2; IBMX, 3-isobutyl-1-methylxanthine; CP, crossing point; 
AREG, Amphiregulin;	  SCG2,	  Secretogranin	  II;	  CCND1,	  cyclin	  D1;	  SST,	  somatostatin;	  EP2R,	  prostaglandin	  E2	  receptor;	  Buta,	  butaprost;	  	  8-­‐CPT-­‐2Me-­‐cAMP,	  8-­‐(4-­‐Chlorophenylthio)-­‐2'-­‐
O-­‐methylad-­‐enosine-­‐3',5'-­‐cyclic	  monophosphate	  sodium	  salt;	  8-­‐Br-­‐cAMP,	  8-­‐Bromoadenosine	  3′,5′-­‐cyclic	  monophosphate;	  p38	  MAPK,	  p38	  Mitogen-­‐activated	  protein	  kinase;	  PI3K,	  phosphatidylinositol	  3-­‐kinase;	  PGE2,	  prostaglandin	  E2;	  	  qRT-­‐PCR,	  quantitative	  reverse	  transcriptase	  polymerase	  chain	  reaction;	  C/EBP,	  CCAAT-­‐enhancer-­‐
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binding	  protein;	  RNAi,	  RNA	  interference;	  PDE,	  phosphodiesterase;	  AKAP,	  A	  Kinase	  Anchoring	  Protein.	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Abstract Adenylyl	  cyclase	  (AC)	  isoforms	  differ	  in	  their	  tissue	  distribution,	  cellular	  localization,	  regulation,	  and	  protein	  interactions.	  	  Most	  cell	  types	  express	  multiple	  AC	  isoforms.	  	  We	  hypothesized	  that	  cAMP	  produced	  by	  different	  AC	  isoforms	  regulates	  unique	  cellular	  responses	  in	  human	  bronchial	  smooth	  muscle	  cells	  (BSMC).	  	  Overexpression	  of	  AC2,	  AC3	  or	  AC6	  had	  distinct	  effects	  on	  forskolin	  (Fsk)-­‐induced	  expression	  of	  a	  number	  of	  known	  cAMP-­‐responsive	  genes.	  	  These	  data	  show	  that	  different	  AC	  isoforms	  can	  differentially	  regulate	  gene	  expression.	  	  Most	  notable,	  overexpression	  and	  activation	  of	  AC2	  enhanced	  interleukin	  6	  (IL-­‐6)	  expression,	  but	  overexpression	  of	  AC3	  or	  AC6	  had	  no	  effect.	  	  IL-­‐6	  production	  by	  BSMC	  was	  induced	  by	  Fsk	  and	  select	  G	  protein-­‐coupled	  receptor	  (GPCR)	  agonists,	  though	  IL-­‐6	  levels	  did	  not	  directly	  correlate	  with	  global	  cAMP	  levels.	  	  Treatment	  with	  PKA	  selective	  6-­‐Bnz-­‐cAMP	  or	  Epac	  selective	  8-­‐CPT-­‐2Me-­‐cAMP	  cAMP	  analogs	  revealed	  a	  predominant	  role	  for	  PKA	  in	  cAMP-­‐mediated	  induction	  of	  IL-­‐6.	  	  IL-­‐6	  promoter	  mutations	  demonstrated	  that	  AP-­‐1	  and	  CRE	  transcription	  sites	  were	  required	  for	  Fsk	  to	  stimulate	  IL-­‐6	  expression.	  	  Our	  present	  study	  defines	  an	  AC2	  cAMP-­‐signaling	  compartment	  that	  specifically	  regulates	  IL-­‐6	  expression	  in	  BSMC	  via	  Epac	  and	  PKA	  and	  demonstrates	  that	  other	  AC	  isoforms	  are	  excluded	  from	  this	  pool.	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Introduction	  	  Bronchial	  smooth	  muscle	  cells	  (BSMC),	  which	  possess	  secretory	  and	  contractile	  properties,	  are	  involved	  in	  the	  airway	  hyper-­‐responsiveness,	  constriction,	  and	  remodeling	  that	  occur	  in	  asthma	  (Tliba	  and	  Panettieri	  2009).	  	  Airway	  constriction	  is	  treated	  with	  β-­‐adrenergic	  receptor	  (βAR)	  agonists,	  which	  stimulate	  smooth	  muscle	  relaxation	  and	  bronchodilation	  through	  cAMP	  signaling	  pathways.	  	  In	  addition	  to	  relaxation,	  βAR	  activation	  also	  stimulates	  secretory	  functions	  of	  airway	  smooth	  muscle.	  	  Interleukin	  6	  (IL-­‐6),	  a	  pro-­‐inflammatory	  cytokine,	  is	  among	  the	  proteins	  secreted	  by	  BSMC	  following	  exposure	  to	  βAR	  agonists	  (Ammit	  et	  al.	  2002).	  	  IL-­‐6	  levels	  are	  increased	  in	  blood	  serum	  and	  sputum	  of	  asthmatics	  and	  are	  inversely	  correlated	  with	  forced	  expiratory	  volume	  (Yokoyama	  et	  al.	  1995;	  Rincon	  and	  Irvin	  2012).	  βAR	  agonists	  stimulate	  Gαs-­‐coupled	  β2AR	  in	  smooth	  muscle,	  activating	  adenylyl	  
cyclases	  (AC)	  that	  catalyze	  the	  formation	  of	  cAMP	  from	  ATP.	  	  	  Recent	  evidence	  suggests	  that	  cAMP	  signaling	  may	  be	  highly	  compartmentized	  in	  BSMC	  such	  that	  distinct	  AC	  isoforms	  regulate	  specific	  cellular	  responses	  such	  as	  arborization	  (Bogard	  et	  al.	  2011;	  Bogard	  et	  al.	  2012).	  	  AC	  isoforms	  differ	  in	  their	  tissue	  distribution,	  cellular	  localization,	  regulation,	  and	  interactions	  with	  other	  proteins	  (Ostrom	  et	  al.	  2012).	  	  Human	  BSMC	  express	  predominantly	  AC2,	  AC4,	  and	  AC6	  (Bogard	  et	  al.	  2011).	  	  AC2	  is	  stimulated	  by	  GβƔ,	  PKC,	  and	  Raf	  kinase;	  it	  is	  not	  significantly	  inhibited	  by	  Gαi	  or	  regulated	  by	  Ca2+	  (Tang	  and	  
Gilman	  1991;	  Bol	  et	  al.	  1997;	  Ding	  et	  al.	  2004;	  Federman	  et	  al.	  1992;	  Feinstein	  et	  al.	  1991).	  	  Conversely,	  Gβɣ,	  PKC,	  Gαi,	  and	  Ca2+	  inhibit	  AC6	  (Bayewitch	  et	  al.	  1998;	  Lai	  et	  al.	  1997;	  Chen	  
and	  Iyengar	  1993;	  Katsushika	  et	  al.	  1992).	  	  AC3	  is	  not	  natively	  expressed	  in	  BSMC,	  but	  it	  is	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of	  interest	  in	  regard	  to	  signaling	  compartments	  since	  it	  falls	  into	  a	  3rd	  subgroup	  of	  AC’s	  as	  defined	  by	  primary	  structure	  and	  regulation:	  Group	  1	  contains	  AC1,	  AC3	  and	  AC8;	  group	  2	  contains	  AC2,	  AC4,	  and	  AC7;	  and	  group	  3	  contains	  AC5	  and	  AC6	  (Patel	  et	  al.	  2001).	  	  AC3	  is	  stimulated	  by	  Ca2+/calmodulin	  (CaM)	  and	  PKC	  and	  inhibited	  by	  CaM	  kinase	  (Choi	  et	  al.	  1992;	  Jacobowitz	  et	  al.	  1993;	  Wei	  et	  al.	  1996).	  	  The	  differences	  among	  AC	  isoforms	  give	  them	  the	  potential	  to	  signal	  in	  unique	  ways	  and	  control	  distinct	  responses	  even	  when	  expressed	  in	  the	  same	  cell.	  We	  hypothesized	  that	  activation	  of	  different	  AC	  isoforms	  leads	  to	  unique	  cellular	  responses,	  including	  changes	  in	  gene	  expression.	  	  In	  BSMC,	  we	  found	  several	  cAMP-­‐regulated	  genes	  that	  were	  differentially	  regulated	  by	  overexpression	  of	  AC2	  or	  AC6,	  while	  AC3	  had	  little	  control	  over	  induction	  of	  these	  genes.	  	  Most	  notably,	  cAMP	  produced	  by	  AC2,	  but	  not	  AC6	  or	  AC3,	  induced	  expression	  of	  IL-­‐6.	  	  This	  specific	  activation	  of	  IL-­‐6	  expression	  appears	  to	  occur	  through	  both	  Epac	  and	  PKA	  signaling	  to	  yield	  activation	  of	  CRE	  and	  AP-­‐1	  elements	  in	  the	  IL-­‐6	  promoter.	  	  	  
	  
Methods	  	  
Cell	  culture:	  Human	  BSMC	  purchased	  from	  Lonza	  were	  grown	  in	  smooth	  muscle	  basal	  medium	  supplemented	  with	  the	  SmGM-­‐2	  bullet	  kit	  (5%	  fetal	  bovine	  serum,	  0.1%	  insulin,	  0.1%	  human	  epidermal	  growth	  factor,	  0.2%	  human	  fibroblast	  growth	  factor-­‐β	  ,and	  gentamicin	  sulfate/amphotericin	  B;	  Lonza).	  	  In	  some	  experiments,	  dialyzed	  FBS	  (Thermo	  Scientific)	  was	  used	  to	  reduce	  induction	  by	  uncontrolled	  stimuli	  in	  serum.	  	  Cells	  were	  kept	  at	  5%	  CO2	  and	  37°	  C.	  	  Experiments	  were	  performed	  on	  cells	  from	  passage	  5-­‐13.	  	  Adenoviral	  constructs	  expressing	  rat	  AC2,	  rat	  AC3,	  mouse	  AC6,	  or	  lacZ	  (control)	  cDNA	  were	  used	  in	  AC	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overexpression	  studies.	  	  The	  titer	  of	  AC	  virus	  was	  chosen	  to	  give	  similar	  global	  cAMP	  levels	  in	  response	  to	  1	  µM	  Fsk.	  	  Cells	  were	  infected	  18-­‐24	  h	  before	  treatment.	  	  	  	  	  	  
Materials:	  Fsk,	  Iso,	  ATPɣS, AVP, PGD2, glucagon, NECA, CGRP, and substance P	  were	  purchased	  from	  Sigma;	  8-­‐CPT-­‐2Me-­‐cAMP,	  GF	  109203X,	  SB	  202190,	  and	  wortmannin	  from	  Tocris,	  and	  butaprost	  from	  Cayman.	  	  IL-­‐6	  promoter	  luciferase	  constructs	  were	  purchased	  from	  the	  Belgian	  Coordinated	  Collections	  of	  Micro-­‐organisms/LMBP;	  LMBP	  acquisition	  numbers	  4495,	  4496,	  4498,	  4499,	  4500	  (Vanden	  Berghe	  et	  al.	  1998;	  Plaisance	  et	  al.	  1997).	  	  	  
cAMP-­‐responsive	  gene	  expression	  and	  GPCR	  gene	  expression:	  Cells	  were	  lysed	  and	  RNA	  was	  isolated	  using	  RNeasy	  kit	  with	  on-­‐column	  DNase	  step	  (Qiagen).	  	  RNA	  purity	  and	  yield	  were	  determined	  with	  Nanodrop	  spectrophotometer.	  	  1	  µg	  RNA	  was	  reverse	  transcribed	  using	  RT2	  first	  strand	  kit	  (SABioscience).	  	  cDNA	  from	  a	  single	  sample	  was	  combined	  with	  RT2	  SYBR	  Green	  Master	  Mix	  (SABioscience)	  and	  distributed	  among	  wells	  of	  a	  multiwell	  plate	  containing	  gene	  specific	  and	  control	  primers	  on	  Human	  cAMP/Ca2+	  PathwayFinder	  or	  Human	  G	  Protein	  Coupled	  Receptors	  384HT	  RT²	  Profiler™	  PCR	  Array	  (SABioscience).	  	  The	  crossing	  point	  (CP)	  was	  determined	  by	  the	  second	  derivative	  maximum	  algorithm	  on	  Roche	  Lightcycler	  480.	  	  Melt	  curve	  analysis	  was	  used	  to	  exclude	  any	  gene	  whose	  CP	  may	  have	  been	  artificially	  reduced	  by	  multiple	  amplification	  products.	  	  Fold	  change	  was	  calculated	  by	  ΔΔCP	  method.	  	  	  
Quantitation	  of	  IL-­‐6	  expression:	  IL-­‐6	  mRNA	  was	  quantified	  in	  cells	  following	  treatment	  with	  the	  indicated	  drug	  or	  vehicle	  for	  1	  h	  (peak	  time	  determined	  from	  time-­‐course	  studies).	  	  RNA	  was	  isolated	  as	  described	  in	  gene	  expression	  studies	  above.	  	  1	  µg	  RNA	  was	  reverse	  transcribed	  using	  Transcriptor	  First	  Strand	  cDNA	  Synthesis	  Kit	  (Roche)	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and	  oligo	  (dT)18	  primer.	  	  PCR	  was	  carried	  out	  on	  Roche	  Lightcycler	  480	  and	  amplification	  detected	  by	  SYBR	  green	  (KAPA).	  	  Single	  PCR	  products	  were	  confirmed	  by	  melt	  curve	  analysis.	  	  Fold	  regulation	  was	  calculated	  by	  ΔΔCP	  method	  with	  normalization	  to	  RPL13A	  housekeeping	  gene.	  	  	  	  IL-­‐6	  Forward:	  	  GAC	  AGC	  CACTCA	  CCT	  CTT	  CA	  IL-­‐6	  Reverse:	  	  	  AGT	  GCCTCT	  TTG	  CTG	  CTT	  TC	  	  	  In	  other	  studies,	  IL-­‐6	  protein	  in	  cell	  culture	  media	  was	  quantified	  using	  a	  sandwich	  ELISA.	  	  Cells	  were	  treated	  with	  the	  indicated	  drug	  or	  vehicle	  for	  24	  h	  (peak	  time	  determined	  from	  time-­‐course	  studies)	  then	  culture	  media	  was	  collected.	  	  ELISA	  were	  used	  to	  quantify	  IL-­‐6	  protein	  in	  each	  sample	  according	  to	  manufacturer’s	  instructions	  (eBioscience).	  	  Absorbance	  was	  quantified	  using	  a	  Synergy	  HT	  (Biotek)	  plate	  reading	  spectrophotometer.	  
cAMP	  assays:	  Cells	  were	  washed	  three	  times	  with	  serum-­‐	  and	  NaHCO3-­‐free	  Dulbecco's	  Modified	  Eagle's	  medium	  (DMEM)	  supplemented	  with	  20	  mM	  HEPES,	  pH	  7.4	  (DMEH).	  After	  equilibration	  at	  37	  ̊C	  for	  30	  min,	  cells	  were	  pretreated	  with	  0.2	  mM	  IBMX	  (a	  broadly	  specific	  PDE	  inhibitor)	  then	  exposed	  to	  the	  indicated	  drug	  for	  10	  min.	  	  Assay	  medium	  was	  aspirated	  and	  150	  μL	  5%	  trichloroacetic	  acid	  was	  added	  to	  each	  well	  to	  terminate	  the	  reaction.	  cAMP	  content	  of	  the	  lysis	  buffer	  extract	  was	  quantified	  using	  the	  cAMP	  EIA	  Kit	  (Cayman	  Chemical)	  using	  the	  manufacturer’s	  acetylation	  protocol.	  
pIL6	  Luciferase	  assays:	  	  BSMC	  were	  plated	  30,000	  cells	  per	  well	  in	  12-­‐well	  plates.	  	  18-­‐24	  h	  after	  plating,	  each	  well	  was	  transfected	  with	  1.8	  µg	  plasmid	  expressing	  the	  human	  IL-­‐6	  promoter	  (wild	  type	  or	  containing	  promoter	  site	  mutations)	  driving	  firefly	  luciferase.	  	  Cells	  were	  co-­‐transfected	  with	  0.4	  µg	  Renilla	  luciferase	  intended	  as	  an	  internal	  control	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constitutively	  expressed	  via	  the	  thymidine	  kinase	  promoter.	  	  However,	  Fsk	  treatment	  affected	  Renilla	  luciferase	  expression,	  so	  it	  could	  not	  be	  used	  for	  normalization	  in	  our	  studies.	  	  All	  transfections	  used	  the	  CalPhos	  (Clontech)	  calcium	  phosphate	  kit.	  	  Experiments	  were	  begun	  48	  h	  post-­‐transfection.	  	  Following	  treatment	  with	  the	  indicated	  drugs	  for	  6	  h,	  cells	  were	  scraped	  in	  250	  µL	  passive	  lysis	  buffer	  and	  assayed	  using	  the	  Dual	  Luciferase	  Reporter	  Assay	  System	  (Promega).	  	  Luminescence	  was	  measured	  with	  a	  TD-­‐20/20	  luminometer	  (Turner	  Designs).	  	  	  
Data	  Analysis	  and	  Statistics:	  Data	  are	  presented	  as	  the	  mean	  ±	  SEM.	  Statistical	  comparisons	  (t	  tests	  and	  one-­‐way	  analysis	  of	  variance)	  were	  performed	  and	  graphics	  were	  generated	  using	  GraphPad	  Prism	  5.0f	  (GraphPad	  Software	  Inc.,	  San	  Diego,	  CA).	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Results	  
Individual	  AC	  isoforms	  differentially	  regulate	  gene	  expression	  in	  BSMC	  Since	  most	  cells	  express	  multiple	  AC	  isoforms,	  we	  were	  interested	  in	  whether	  different	  AC’s	  mediate	  different	  cellular	  responses.	  We	  used	  adenoviral	  vectors	  to	  overexpress	  AC2,	  AC3,	  AC6,	  or	  lacZ	  (control)	  in	  BSMC.	  	  Stimulation	  with	  1	  µM	  Fsk	  significantly	  increased	  cAMP	  accumulation	  in	  all	  cells,	  as	  measured	  by	  EIA	  in	  the	  presence	  of	  broad-­‐spectrum	  PFE	  inhibitor	  IBMX	  (Fig.	  1).	  	  Overexpression	  of	  AC	  did	  not	  significantly	  increase	  basal	  or	  Fsk	  stimulated	  cAMP	  accumulation,	  but	  downstream	  responses,	  including	  gene	  expression,	  were	  modulated	  by	  AC	  overexpression	  (Fig.	  2a).	  	  To	  investigate	  whether	  cAMP	  signaling	  by	  individual	  AC	  isoforms	  has	  unique	  effects	  on	  gene	  expression	  in	  BSMC,	  we	  used	  PCR	  arrays	  to	  examine	  expression	  of	  84	  cAMP	  and	  Ca2+-­‐sensitive	  genes.	   We looked 
for changes resulting from overexpression and activation of specific AC isoforms.  Adenoviral 
vectors were used to overexpress AC2, AC3, AC6, or lacZ, and RNA	  was	  isolated	  following	  24	  h	  exposure	  to	  1	  µM	  Fsk.	  	  Fsk	  altered	  the	  expression	  of	  many	  of	  these	  genes	  compared	  to	  vehicle	  in	  control	  BSMC,	  but	  we	  focused	  on	  genes	  that	  were	  differentially	  regulated	  with	  overexpression	  of	  AC	  isoforms	  by	  graphing	  mRNA	  expression	  as	  fold	  change	  compared	  to	  the	  lacZ	  condition	  (Supplementary	  Table	  1	  and	  Fig.	  2a).	  	  A 3-fold or greater change was used 
to distinguish genes that were up-regulated or down-regulated upon AC overexpression, but 
smaller changes could be physiologically significant.  Overexpression of AC3 did not cause a 3-
fold or greater change compared to control cells in any of the genes on the array.  AC2 and AC6 
overexpression could enhance or dampen Fsk induction and had differing effects depending on 
the AC isoform and the gene.  A total of 13 genes were altered by AC overexpression, and a 
subset was chosen to highlight the diversity in responses (Fig.	  2a).  Complete array data is 
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presented in Supplementary Table 1.  Fsk-­‐mediated	  expression	  of	  Amphiregulin	  (AREG)	  was	  augmented	  to	  a	  greater	  extent	  by	  AC6	  overexpression	  than	  by	  AC2.	  	  AC2	  overexpression	  reduced	  the	  expression	  of	  Secretogranin	  II	  (SCG2),	  while	  AC6	  overexpression	  reduced	  the	  expression	  of	  cyclin	  D1	  (CCND1).	  	  Fsk-­‐mediated	  expression	  of	  Interleukin	  6	  (IL-­‐6)	  was	  enhanced	  only	  by	  AC2	  overexpression	  and	  somatostatin	  (SST)	  was	  enhanced	  only	  by	  AC6	  overexpression.	  	  cAMP produced by AC2 and AC6, but not AC3, were able to signal to the 
nucleus where they had unique effects on gene expression.  These	  data	  indicate	  that	  different	  AC	  isoforms	  generate	  signals	  that	  are	  interpreted	  in	  distinct,	  even	  contrasting,	  ways	  in	  the	  nucleus.	  	  
AC2	  overexpression	  enhances	  Fsk-­‐	  and	  receptor-­‐mediated	  induction	  of	  IL-­‐6	  gene	  
expression	  The	  AC2-­‐specific	  effect	  on	  regulation	  of	  IL-­‐6	  expression	  and	  IL-­‐6‘s	  role	  in	  asthma	  pathogenesis	  caused	  us	  to	  look	  further	  into	  how	  AC2-­‐derived	  cAMP	  is	  uniquely	  able	  to	  regulate	  IL-­‐6.	  	  Fsk	  directly	  activates	  all	  adenylyl	  cyclases	  natively	  expressed	  in	  BSMC,	  yet	  only	  AC2	  overexpression	  increased	  IL-­‐6	  mRNA	  levels	  compared	  to	  control	  cells.	  	  To	  determine	  if	  the	  AC2	  enhancement	  of	  IL-­‐6	  mRNA	  expression	  translates	  to	  increased	  protein,	  we	  measured	  secreted	  IL-­‐6	  in	  cell	  culture	  media	  using	  an	  ELISA.	  	  	  AC2	  overexpression	  increased	  IL-­‐6	  produced	  in	  response	  to	  Fsk	  by	  38.01%	  compared	  to	  lacZ,	  but	  AC6	  overexpression	  did	  not	  enhance	  Fsk	  stimulated	  IL-­‐6	  production	  (Fig.	  2b).	  	  Again,	  the	  results	  are	  graphed	  with	  respect	  to	  lacZ	  to	  emphasize	  the	  effect	  of	  overexpressing	  each	  AC	  isoform.	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We	  hypothesized	  that	  co-­‐localization	  of	  receptors,	  cyclases,	  and	  downstream	  effectors	  create	  distinct	  cAMP	  signaling	  compartments	  in	  BSMC.	  	  We	  have	  previously	  shown	  that	  AC2	  and	  prostaglandin	  E2	  receptors	  (EP2R)	  are	  excluded	  from	  lipid	  rafts	  in	  BSMC,	  and	  that	  β2AR	  are	  predominately	  localized	  to	  lipid	  rafts	  where	  they	  co-­‐localize	  with	  AC6	  (Bogard	  et	  al.	  2011).	  	  Thus,	  we	  stimulated	  β2AR	  with	  isoproterenol	  (Iso)	  or	  EP2R	  with	  butaprost	  (Buta)	  for	  24	  h	  and	  measured	  IL-­‐6	  secreted	  into	  culture	  supernatant	  by	  ELISA.	  	  Both	  Iso	  and	  Buta	  increased	  IL-­‐6	  production,	  and	  these	  responses	  were	  enhanced	  by	  AC2	  overexpression	  but	  not	  AC6	  overexpression	  (Fig.	  2b).	  Overexpression	  of	  AC2	  enhanced	  Iso-­‐stimulated	  IL-­‐6	  production	  by	  48.44%	  and	  Buta-­‐stimulated	  response	  by	  32.41%.	  	  AC6	  overexpression	  did	  not	  enhance	  IL-­‐6	  production	  over	  control	  cells	  in	  response	  to	  any	  of	  the	  stimuli	  we	  tested.	  	  Therefore,	  non-­‐raft	  AC2	  seems	  to	  have	  preferential	  control	  over	  IL-­‐6	  expression,	  and	  can	  be	  stimulated	  by	  both	  EP2R	  and	  β2AR.	  	  β2AR	  have	  been	  described	  as	  being	  lipid	  raft	  localized	  but	  appear	  to	  translocate	  into	  non-­‐raft	  domains	  upon	  activation	  (Ostrom	  et	  al.	  2001;	  Rybin	  et	  al.	  2000).	  	  	  
Only	  some	  GPCR	  are	  associated	  with	  IL-­‐6	  induction	  Having	  found	  that	  both	  β2AR	  and	  EP2R	  were	  linked	  to	  IL-­‐6	  expression	  in	  AC2	  overexpressing	  BSMC,	  we	  wondered	  if	  there	  are	  other	  Gαs	  -­‐coupled	  receptors	  that	  are	  able	  to	  stimulate	  IL-­‐6	  expression	  in	  BSMC.	  	  Because	  cells	  can	  express	  many	  receptors,	  we	  first	  wanted	  to	  identify	  the	  GPCR	  expressed	  in	  BSMC.	  	  We	  used	  a	  384-­‐well	  qRT-­‐PCR	  array	  to	  look	  for	  expression	  of	  mRNA	  encoding	  many	  different	  GPCR	  (Supplementary	  Table	  2).	  	  Following	  amplification,	  SYBR	  green	  melt	  curves	  were	  analyzed,	  and	  genes	  with	  more	  than	  1	  peak	  were	  excluded	  due	  to	  the	  ambiguity	  associated	  with	  multiple	  products.	  	  It	  is	  
	   13	  
important	  to	  note	  that	  the	  PCR	  array	  data	  are	  qualitative	  in	  this	  context.	  	  Since	  cDNA	  for	  each	  receptor	  was	  amplified	  with	  different	  primers	  resulting	  in	  products	  of	  varying	  lengths,	  receptors	  with	  lower	  CP	  values	  are	  not	  necessarily	  expressed	  at	  higher	  levels.	  	  The	  PCR	  array	  served	  as	  a	  starting	  point	  to	  discover	  all	  the	  GPCR	  expressed	  by	  BSMC,	  but	  ultimately	  other	  approaches	  must	  be	  used	  to	  confirm	  functional	  receptor	  expression.	  	  	  mRNA	  was	  detected	  (CP	  <35)	  for	  227	  of	  the	  receptors	  examined,	  while	  mRNA	  was	  not	  detected	  (CP	  >35)	  for	  81	  receptors	  (Supplementary	  Table	  2).	  	  We	  chose	  a	  subset	  of	  the	  receptors	  with	  readily	  detectible	  mRNA	  and	  measured	  cAMP	  and	  IL-­‐6	  production	  following	  stimulation	  with	  their	  receptor-­‐specific	  agonists.	  	  IL-­‐6	  protein	  in	  culture	  media	  increased	  compared	  to	  vehicle	  following	  24	  h	  treatment	  with	  a	  purinergic	  receptor	  agonist,	  ATPƔS, or	  adenosine	  receptor	  agonist,	  5'-­‐N-­‐ethylcarboxamidoadenosine	  (NECA, Fig. 3a).  Arginine 
vasopressin (AVP), BRL 37344 (β3AR-selective agonist), α-calcitonin gene related peptide (α-
CGRP), glucagon, prostaglandin D2 (PGD2), and substance P did not significantly increase IL-6 
secretion compared to vehicle.  We also tested these agonists for their ability to stimulate cAMP 
production in BSMC.  Cells were treated with these same GPCR-selective agonists for 10 min in 
the presence of a broad-spectrum phosphodiesterase (PDE) inhibitor (0.2 mM IBMX). ATPƔS 
and NECA, agonists that increased IL-6 secretion, did not significantly increase global cAMP 
levels (Fig. 3b).  The cAMP response to NECA may be blunted by antagonism of adenosine 
receptors by IBMX (Daly et al. 1987).  BRL 37344 and glucagon, agonists that did not increase 
IL-6 production, induced small but non-significant cAMP responses.  These data may indicate 
that not all GPCR-mediated cAMP responses are capable of eliciting IL-6 production and that 
cAMP may not be the only signal required to elicit the response.	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Global	  cAMP	  levels	  are	  not	  directly	  correlated	  to	  IL-­‐6	  induction	  Since	  levels	  of	  IL-­‐6	  production	  do	  not	  appear	  to	  directly	  correlate	  with	  global	  cAMP	  levels,	  we	  decided	  to	  further	  examine	  the	  correlation	  between	  cAMP	  and	  IL-­‐6	  using	  agonists	  for	  β2AR	  and	  EP2R,	  receptors	  whose	  expression	  in	  BSMC	  and	  ability	  to	  stimulate	  IL-­‐6	  in	  other	  cell	  types	  have	  been	  better	  described	  (Bogard	  et	  al.	  2011;	  Raychaudhuri	  et	  al.	  2010;	  Chen	  et	  al.	  2012).	  	  Simultaneous	  Gαs	  and	  Fsk	  stimulation	  produces	  a	  synergistic	  cAMP	  response	  in	  many	  cell	  types	  that	  can	  aid	  in	  determining	  the	  role	  of	  this	  signaling	  pathway	  (Insel	  and	  Ostrom	  2003;	  Daly	  et	  al.	  1982;	  Darfler	  et	  al.	  1982;	  Sutkowski	  et	  al.	  1994;	  Ostrom	  et	  al.	  2000).	  	  We	  used	  Iso	  and	  Buta	  alone	  or	  with	  concurrent	  treatment	  with	  Fsk	  (0.1	  µM)	  to	  determine	  if	  increased	  cAMP	  always	  translates	  to	  increased	  IL-­‐6	  production.	  	  Lower	  concentrations	  of	  each	  drug	  were	  used	  in	  order	  to	  observe	  synergistic	  effects.	  	  Addition	  of	  Fsk	  at	  the	  time	  of	  agonist	  stimulation	  increased	  cAMP	  production	  over	  agonist	  alone	  but	  increased	  intra-­‐experiment	  variability	  (Fig.	  4a).	  	  Thus,	  BSMC	  express	  a	  moderate	  Gαs-­‐Fsk	  synergistic	  effect.	  	  	  Using	  these	  same	  conditions,	  we	  found	  absolutely	  no	  increase	  in	  IL-­‐6	  production	  (Fig.	  4b).	  	  Therefore,	  higher	  cAMP	  levels	  may	  not	  translate	  to	  increased	  IL-­‐6	  expression,	  implying	  that	  other	  signaling	  pathways	  could	  be	  involved.	  We	  next	  sought	  to	  determine	  which	  downstream	  effectors	  are	  associated	  with	  AC2-­‐mediated	  induction	  of	  IL-­‐6	  expression.	  	  PKA	  and	  Epac	  are	  the	  effectors	  of	  intracellular	  cAMP.	  	  We	  used	  selective	  cAMP	  analogs	  to	  investigate	  the	  role	  of	  these	  two	  pathways	  in	  regulation	  of	  IL-­‐6	  expression.	  	  Cells	  were	  cultured	  in	  medium	  containing	  dialyzed	  FBS	  to	  reduce	  other	  stimuli	  present	  in	  serum.	  	  	  8-­‐CPT-­‐2Me-­‐cAMP,	  the	  Epac	  selective	  analog,	  did	  not	  significantly	  increase	  IL-­‐6	  compared	  to	  vehicle	  at	  concentrations	  ranging	  from	  1	  µM	  to	  100	  µM	  (Fig.	  5).	  	  The	  PKA	  selective	  analog	  6-­‐Bnz-­‐cAMP	  stimulated	  a	  significant	  increase	  in	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IL-­‐6	  production	  when	  cells	  were	  exposed	  to	  100	  µM.	  	  Treatment	  with	  the	  non-­‐selective	  cAMP	  analog	  8-­‐Br-­‐cAMP	  that	  acts	  through	  both	  PKA	  and	  Epac	  resulted	  in	  	  significantly	  greater	  IL-­‐6	  production	  than	  analogs	  acting	  through	  PKA	  or	  Epac	  alone.	  	  PKA	  appears	  to	  play	  a	  predominant	  role	  in	  cAMP	  mediated	  induction	  of	  IL-­‐6.	  	  Activation	  of	  Epac	  alone	  did	  not	  significantly	  increase	  IL-­‐6	  production,	  but	  Epac	  signaling	  appears	  to	  synergize	  with	  PKA	  signaling	  to	  contribute	  to	  IL-­‐6	  induction.	  	  	  
  	  
Fsk-­‐induced	  IL-­‐6	  expression	  is	  not	  affected	  by	  inhibition	  of	  PKC,	  p38	  MAPK,	  or	  PI3K	  cAMP	  can	  induce	  IL-­‐6	  through	  various	  signaling	  pathways,	  with	  differences	  among	  cell	  types.	  	  In	  astrocytes,	  Prostaglandin	  E2	  (PGE2)	  enhances	  IL-­‐6	  expression	  through	  EP4-­‐like	  receptors	  and	  p38	  mitogen-­‐activated	  protein	  kinase	  (p38	  MAPK)	  and	  protein	  kinase	  C	  (PKC)	  pathways	  (Fiebich	  et	  al.	  2001).	  	  	  In	  chondrocytes	  the	  same	  stimulus	  regulates	  IL-­‐6	  expression	  through	  PKA	  and	  phosphatidylinositol	  3-­‐kinase	  (PI3K)	  pathways	  (Wang	  et	  al.	  2010).	  	  IL-­‐6	  induction	  by	  βAR	  activation	  in	  neonatal	  mouse	  cardiac	  fibroblasts	  is	  Epac-­‐dependent	  and	  involves	  PKCδ	  and	  p38	  MAPK	  signaling	  pathways	  (Chen	  et	  al.	  2012).	  	  Since	  it	  is	  clear	  that	  pathways	  mediating	  cAMP	  induction	  of	  IL-­‐6	  are	  cell-­‐type	  specific,	  we	  sought	  to	  determine	  which	  signaling	  intermediates	  are	  required	  for	  Fsk-­‐induced	  IL-­‐6	  expression	  in	  BSMC.	  	  	  We	  used	  inhibitors	  of	  PKC	  (GF	  109203X),	  p38	  MAP	  kinase	  (SB	  202190),	  or	  PI3K	  (wortmanin)	  to	  probe	  for	  the	  role	  of	  these	  signaling	  pathways.	  	  Cells	  were	  pretreated	  for	  1	  h	  with	  10	  µM	  of	  each	  inhibitor,	  concentrations	  that	  significantly	  inhibited	  IL-­‐6	  expression	  in	  other	  cell	  types	  (Fiebich	  et	  al.	  2001;	  Wang	  et	  al.	  2010).	  	  Following	  inhibitor	  pretreatment,	  cells	  were	  exposed	  to	  1	  µM	  Fsk	  for	  1	  h,	  and	  IL-­‐6	  mRNA	  expression	  was	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measured	  by	  qRT-­‐PCR.	  	  None	  of	  the	  inhibitors	  tested	  had	  a	  significant	  inhibitory	  effect	  on	  Fsk-­‐stimulated	  IL-­‐6	  expression	  (Fig.	  6).	  	  In	  fact,	  GF	  109203X	  or	  wortmanin	  pretreatment	  tended	  to	  increase	  IL-­‐6	  production	  compared	  to	  Fsk	  alone	  (not	  significant,).	  	  Since	  nonspecific	  effects	  could	  occur	  at	  high	  concentrations,	  we	  tested	  each	  inhibitor	  at	  concentrations	  ranging	  from	  10	  nM	  to	  10	  µM.	  	  There	  was	  no	  inhibition	  of	  Fsk-­‐induced	  IL-­‐6	  expression	  by	  this	  range	  of	  concentrations	  of	  any	  of	  the	  inhibitors	  tested	  (data	  not	  shown).	  	  If	  anything,	  these	  inhibitors	  slightly	  increased	  Fsk-­‐induced	  IL-­‐6	  expression.	  	  cAMP-­‐mediated	  regulation	  of	  IL-­‐6	  expression	  may	  involve	  multiple	  stimulatory	  and	  inhibitory	  pathways	  with	  substantial	  cross	  talk	  and	  redundancy,	  making	  it	  difficult	  to	  unravel	  the	  steps	  with	  inhibition	  of	  individual	  intermediate	  kinases.	  	  	  	  	  	  
AP-­‐1	  and	  CRE	  promoter	  elements	  are	  required	  for	  Fsk-­‐stimulated	  IL-­‐6	  expression	  We	  utilized	  IL-­‐6	  gene	  reporter	  assays	  as	  an	  alternative	  approach	  to	  understand	  the	  signaling	  pathways	  linking	  cAMP	  to	  IL-­‐6	  expression.	  	  The	  IL-­‐6	  promoter	  contains	  C/EBP,	  CRE,	  NF-­‐κB, and 2	  AP-­‐1	  sites	  (Dendorfer	  et	  al.	  1994;	  Akira	  et	  al.	  1990;	  Tanabe	  et	  al.	  1988).	  	  
We	  transfected	  BSMC	  with	  a	  construct	  containing	  the	  luciferase	  gene	  preceded	  by	  1168	  base	  pairs	  of	  the	  wild	  type	  human	  IL-­‐6	  promoter.	  	  Fsk	  treatment	  (1	  µM)	  increased	  luciferase	  activity	  nearly	  4-­‐fold	  in	  cells	  transfected	  with	  the	  wild	  type	  promoter	  construct	  (Fig.	  7).	  	  To	  determine	  which	  promoter	  elements	  play	  a	  role	  in	  Fsk-­‐stimulated	  IL-­‐6	  expression,	  we	  then	  transfected	  different	  luciferase	  constructs	  containing	  point	  mutations	  in	  each	  specific	  promoter	  element.	  	  Mutations	  to	  the	  5’	  AP-­‐1	  or	  the	  CRE	  transcription	  sites	  significantly	  reduced	  Fsk-­‐stimulated	  reporter	  activity	  compared	  to	  wild	  type.	  	  Mutation	  of	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C/EBP	  or	  NF-­‐κB	  promoter	  sites	  did	  not	  significantly	  alter	  the	  Fsk	  response.	  	  Thus,	  Fsk	  selectively	  leads	  to	  activation	  of	  AP-­‐1	  and	  CRE	  driven	  expression	  of	  IL-­‐6.	  	  	  
Discussion	  All	  AC’s	  catalyze	  the	  conversion	  of	  ATP	  to	  cAMP,	  but	  the	  cAMP	  pools	  created	  by	  different	  AC	  isoforms	  can	  have	  unique	  effects	  in	  a	  cell	  (Gros	  et	  al.	  2006;	  Bogard	  et	  al.	  2012).	  	  We	  sought	  to	  determine	  whether	  cAMP	  from	  different	  AC	  isoforms	  differentially	  regulates	  gene	  expression	  in	  BSMC.	  Overexpression	  of	  AC2	  or	  AC6	  at	  the	  levels	  we	  achieved	  in	  these	  studies	  did	  not	  significantly	  increase	  cAMP	  accumulation	  measured	  by	  EIA	  in	  the	  presence	  IBMX	  (Fig.	  1).	  	  cAMP	  production	  was	  likely	  underestimated	  since	  IBMX-­‐insensitive	  PDE8	  is	  expressed	  in	  BSMC.	  	  Overexpression	  of	  AC	  increases	  phosphorylation	  of	  PDE8	  in	  these	  cells	  (unpublished	  observations),	  which	  increases	  its	  activity	  (Brown	  et	  al.	  2012).	  	  Although	  adenoviral	  overexpression	  did	  not	  cause	  a	  significant	  increase	  in	  Fsk-­‐stimulated	  global	  cAMP	  levels,	  it	  did	  significantly	  alter	  downstream	  signaling	  and	  cellular	  responses.	  	  AC	  overexpression	  influences	  Fsk-­‐mediated	  gene	  regulation	  (Fig.	  1	  and	  Supplementary	  Table	  1)	  and	  phosphorylation	  of	  several	  proteins	  (unpublished).	  	  AC	  can	  regulate	  some	  signaling	  pathways	  following	  stimulation	  independent	  from	  production	  of	  cAMP	  via	  changes	  in	  protein	  interactions	  (Gao	  and	  Hammond	  2011;	  Gao	  et	  al.	  2011).	  	  We	  hypothesize	  that	  cAMP	  signaling	  compartments	  facilitate	  rapid	  and	  focused	  signal	  transduction	  downstream	  of	  AC	  such	  that	  individual	  AC	  isoforms	  could	  mediate	  cellular	  responses	  without	  a	  significant	  increase	  in	  cytosolic	  cAMP	  levels.	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  We	  compared	  expression	  of	  84	  cAMP-­‐sensitive	  genes	  in	  cells	  overexpressing	  AC2,	  AC3,	  or	  AC6	  to	  control	  BSMC	  endogenously	  expressing	  AC2,	  AC4,	  and	  AC6.	  	  	  Subtractive	  analysis	  showed	  that	  there	  are	  at	  least	  three	  distinct	  cAMP	  signaling	  compartments	  created	  by	  overexpression	  of	  these	  different	  AC	  isoforms.	  	  Exogenously	  expressed	  AC3	  produces	  cAMP	  in	  a	  compartment	  that	  is	  not	  linked	  to	  regulation	  of	  the	  genes	  we	  examined.	  	  cAMP	  pools	  produced	  by	  AC2	  and	  AC6	  are	  able	  to	  regulate	  cAMP-­‐responsive	  genes,	  and	  for	  some	  genes	  there	  are	  isoform-­‐specific	  effects	  on	  regulation.	  	  cAMP	  from	  AC2	  and	  AC6	  can	  stimulate	  or	  inhibit	  expression	  of	  different	  genes,	  and	  each	  cAMP	  pool	  can	  have	  contrasting	  effects	  on	  a	  given	  gene.	  	  	  Regulation	  of	  gene	  expression	  by	  cAMP	  has	  been	  studied	  for	  decades,	  but	  not	  in	  the	  context	  of	  cAMP	  produced	  by	  specific	  AC	  isoforms.	  	  Activation	  of	  a	  gene	  via	  PKA-­‐phosphorylation	  of	  CREB	  was	  first	  described	  for	  the	  somatostatin	  gene	  (Montminy	  and	  Bilezikjian	  1987).	  	  We	  find	  that	  the	  induction	  of	  SST	  occurs	  downstream	  of	  AC6,	  but	  not	  of	  AC2,	  in	  BSMC.	  	  cAMP	  produced	  by	  AC2	  can	  induce	  other	  genes	  that	  contain	  CREB	  responsive	  elements	  in	  these	  cells,	  raising	  the	  question	  of	  how	  these	  same	  cAMP	  signals	  are	  interpreted	  differently	  in	  the	  nucleus.	  	  	  	  Activation	  of	  AC2,	  but	  not	  AC6,	  is	  associated	  with	  induction	  of	  IL-­‐6	  mRNA	  expression	  and	  protein	  production.	  	  To	  better	  understand	  how	  cAMP	  from	  the	  AC2	  compartment	  specifically	  regulates	  IL-­‐6	  expression,	  we	  investigated	  the	  downstream	  signaling	  pathways	  responsible	  for	  activation	  of	  the	  IL-­‐6	  promoter.	  	  Activation	  of	  AC2	  by	  Fsk	  or	  certain	  Gαs-­‐coupled	  receptors	  activates	  Epac	  and	  PKA	  and	  stimulates	  IL-­‐6	  expression	  through	  interactions	  at	  AP-­‐1	  and	  CRE	  sites	  in	  the	  IL-­‐6	  promoter.	  	  Selective	  cAMP	  analogs	  revealed	  a	  predominant	  role	  for	  PKA	  signaling	  in	  cAMP	  mediated	  IL-­‐6	  induction,	  but	  Epac	  signaling	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synergistically	  enhanced	  the	  response	  following	  exposure	  to	  a	  nonselective	  cAMP	  analog	  that	  activates	  both	  PKA	  and	  Epac.	  	  Measures	  of	  bulk	  intracellular	  cAMP	  levels	  are	  not	  correlated	  with	  the	  amount	  of	  IL-­‐6	  produced.	  	  Different	  receptors	  that	  activated	  both	  cAMP	  production	  and	  IL-­‐6	  did	  not	  show	  a	  clear	  relationship	  between	  cAMP	  levels	  and	  IL-­‐6.	  	  Furthermore,	  Gαs-­‐Fsk	  synergism	  led	  to	  increased	  cAMP	  production	  but	  did	  not	  alter	  IL-­‐6	  production.	  	  It	  is	  possible	  that	  there	  is	  a	  threshold	  after	  which	  additional	  cAMP	  has	  no	  ability	  to	  further	  increase	  IL-­‐6	  expression.	  	  However,	  a	  cAMP	  compartment	  model	  might	  also	  help	  explain	  the	  lack	  of	  correlation	  with	  large	  amounts	  of	  cAMP.	  	  If	  cAMP	  is	  not	  produced	  in	  the	  right	  location,	  it	  may	  be	  unable	  to	  activate	  the	  pathways	  that	  enhance	  IL-­‐6	  expression.	  	  Further	  studies	  that	  can	  detect	  cAMP	  produced	  in	  distinct	  subcellular	  compartments	  are	  needed	  to	  understand	  if	  such	  pools	  of	  cAMP	  exist.	  	  The	  signaling	  pathways	  linking	  GPCR	  activation	  to	  induction	  of	  IL-­‐6	  appear	  to	  be	  complex.	  	  ATPɣS	  and	  NECA	  are	  able	  to	  increase	  IL-­‐6	  production	  without	  a	  detectable	  increase	  in	  cAMP,	  implying	  that	  other	  signaling	  pathways	  activated	  by	  Gs-­‐coupled	  receptors	  can	  increase	  IL-­‐6	  expression.	  	  However,	  pharmacological	  inhibition	  of	  PKC,	  p38	  MAPK,	  or	  PI3K	  does	  not	  reduce,	  and	  may	  actually	  increase,	  Fsk-­‐induced	  IL-­‐6	  production	  in	  BSMC.	  	  These	  data	  are	  difficult	  to	  interpret	  due	  to	  the	  possibility	  of	  non-­‐selective	  effects	  of	  these	  inhibitors.	  	  An	  alternative	  approach	  to	  study	  intermediate	  signaling	  molecules	  is	  to	  use	  RNA	  interference,	  which	  allows	  selective	  reduction	  in	  expression	  without	  off	  target	  effects.	  	  However,	  the	  poor	  transfection	  efficiency	  of	  BSMC	  restricted	  our	  ability	  to	  utilize	  RNAi	  in	  the	  present	  study.	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The	  fact	  that	  both	  PKA	  and	  Epac	  are	  activated	  and	  that	  both	  the	  AP-­‐1	  and	  CRE	  promoter	  sequences	  appear	  to	  play	  roles,	  imply	  that	  multiple	  signaling	  pathways	  intersect	  to	  regulate	  IL-­‐6	  production.	  	  Thus,	  the	  compartmentized	  responses	  we	  observe	  may	  be	  partly	  due	  to	  the	  generation	  of	  different	  signal	  patterns	  that	  reach	  the	  nucleus	  rather	  than	  a	  strict	  spatial	  separation	  of	  similar	  signals.	  	  AC2	  and	  AC6	  may	  participate	  in	  different	  compartments	  in	  the	  near-­‐membrane	  region	  that	  leads	  to	  activation	  of	  different	  signals,	  such	  that	  the	  compartment	  does	  not	  need	  to	  be	  maintained	  all	  the	  way	  into	  the	  nucleus.	  	  The	  membrane	  compartments	  likely	  exist	  because	  AC	  isoforms	  differ	  in	  their	  regulation	  and	  interactions	  with	  other	  signaling	  molecules.	  	  AC2	  is	  known	  to	  interact	  with	  multiple	  A	  Kinase	  Anchoring	  Protein	  (AKAP)	  scaffolding	  molecules	  including	  mAKAP,	  Yotiao,	  and	  AKAP79,	  which	  bring	  cAMP	  produced	  by	  AC2	  in	  close	  proximity	  to	  prearranged	  signaling	  cascades	  that	  include	  PDE’s,	  which	  limit	  cAMP	  diffusion	  (Piggott	  et	  al.	  2008;	  Kapiloff	  et	  al.	  2009;	  Scott	  et	  al.	  2013).	  	  Of	  these,	  AKAP79	  has	  been	  identified	  in	  BSMC	  (Horvat	  et	  al.	  2012).	  	  AC2	  specific	  enhancement	  and	  the	  ability	  of	  ATPɣS	  and	  NECA	  to	  induce	  IL-­‐6	  without	  significant	  global	  cAMP	  increase	  could	  be	  explained	  by	  PKC	  activation	  of	  AC2	  as	  part	  of	  a	  complex	  with	  AKAP79	  as	  recently	  described	  by	  Shen	  and	  Cooper	  (2013).	  	  Using	  plasma	  membrane	  targeted	  Epac2	  FRET-­‐based	  cAMP	  sensors	  along	  with	  molecular	  and	  pharmacological	  approaches,	  they	  showed	  that	  activation	  of	  muscarinic	  receptors	  leads	  to	  the	  receptor’s	  association	  with	  AKAP79	  in	  HEK-­‐293	  cells.	  	  AKAP79	  forms	  a	  complex	  containing	  the	  receptor,	  AC2,	  PKC,	  PKA,	  and	  PDE4.	  	  This	  complex	  results	  in	  signals	  that	  are	  confined	  in	  space	  and	  time.	  	  Upon	  stimulation	  of	  the	  muscarinic	  receptor,	  PKC	  activates	  AC2.	  	  The	  cAMP	  produced	  by	  AC2	  is	  short-­‐lived	  since	  it	  activates	  PDE4	  activity	  via	  PKA,	  and	  all	  components	  are	  kept	  in	  close	  association	  by	  AKAP79	  (Shen	  and	  Cooper	  2013).	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It	  is	  likely	  that	  AC6	  is	  also	  part	  of	  signaling	  complexes	  containing	  PDE’s.	  	  PDE4	  appears	  to	  play	  a	  role	  in	  preventing	  cAMP	  produced	  by	  AC6	  from	  inducing	  IL-­‐6	  expression.	  	  When	  we	  treated	  BSMC	  with	  the	  PDE4-­‐selective	  inhibitor	  rolipram,	  overexpression	  of	  AC6	  significantly	  increased	  IL-­‐6	  production,	  even	  at	  basal	  AC	  activity	  (with	  no	  addition	  of	  Fsk,	  data	  not	  shown).	  	  The	  AKAP	  gravin	  orchestrates	  a	  complex	  with	  PDE4	  to	  restrict	  cAMP	  to	  the	  membrane	  region	  (Willoughby	  et	  al.	  2006).	  	  Given	  that	  gravin	  is	  expressed	  in	  airway	  smooth	  muscle	  one	  might	  hypothesize	  that	  this	  complex	  acts	  to	  restrict	  the	  AC6	  signaling	  compartment	  (Horvat	  et	  al.	  2012).	  	  Further	  work	  should	  seek	  to	  define	  all	  the	  proteins	  associated	  with	  AC’s	  natively	  expressed	  in	  BSMC.	  	  Such	  studies	  should	  illuminate	  how	  AC2	  is	  specifically	  linked	  to	  enhancement	  of	  IL-­‐6	  expression	  and	  how	  AC6	  normally	  lacks	  this	  ability,	  and	  how	  AC6	  regulates	  SST	  expression	  but	  AC2	  does	  not.	  We	  hypothesized	  that	  individual	  AC	  isoforms	  can	  differentially	  regulate	  cellular	  responses	  in	  BSMC	  and	  found	  that	  AC2-­‐derived	  cAMP	  selectively	  regulates	  induction	  of	  IL-­‐6	  gene	  expression.	  	  We	  are	  the	  first	  to	  show	  AC	  isoform-­‐specific	  differences	  in	  regulation	  of	  gene	  expression,	  but	  have	  little	  insight	  into	  the	  mechanistic	  details	  behind	  this	  phenomenon.	  	  The	  poor	  transfection	  efficiency	  of	  BSMC	  limits	  the	  approaches	  that	  can	  be	  used	  to	  study	  the	  roles	  for	  individual	  AC	  isoforms	  and	  the	  downstream	  signaling	  molecules	  important	  for	  AC2	  selective	  regulation	  of	  IL-­‐6	  expression.	  	  We	  used	  adenoviral	  overexpression	  of	  individual	  AC	  isoforms	  and	  subtractive	  analysis	  to	  uncover	  AC	  isoform-­‐specific	  roles	  in	  regulating	  gene	  expression.	  	  One	  concern	  with	  using	  an	  overexpression	  approach	  is	  whether	  overexpressed	  AC	  has	  the	  same	  localization	  as	  native	  protein.	  	  Our	  previous	  work	  examined	  subcellular	  localization	  of	  overexpressed	  AC’s	  and	  found	  no	  deviations	  from	  the	  pattern	  of	  endogenous	  expression	  (Bogard	  et	  al.	  2011;	  Bogard	  et	  al.	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2012).	  	  By	  the	  time	  a	  cAMP-­‐mediated	  signal	  has	  reached	  the	  nucleus	  there	  have	  been	  many	  opportunities	  for	  stimulatory	  and	  inhibitory	  signaling	  and	  cross	  talk	  among	  signaling	  pathways,	  which	  make	  it	  difficult	  to	  trace	  an	  AC2-­‐derived	  cAMP	  signal	  all	  the	  way	  to	  the	  IL-­‐6	  promoter.	  	  Future	  work	  will	  look	  at	  isoform	  specific	  differences	  more	  proximal	  to	  AC.	  	  A	  proteomics	  study	  is	  underway	  to	  identify	  phosphorylation	  patterns	  downstream	  of	  individual	  AC	  isoforms	  and	  may	  provide	  insight	  into	  signaling	  intermediates	  and	  pathways	  activated	  selectively	  by	  AC2	  that	  induce	  IL-­‐6	  expression.	  	  	  	  	  The	  present	  work	  illustrates	  that	  AC	  isoforms	  regulate	  specific	  cellular	  responses	  via	  differential	  gene	  expression	  in	  BSMC.	  	  βAR	  agonist-­‐mediated	  AC	  activation	  is	  effective	  for	  treatment	  of	  bronchoconstriction	  in	  asthma,	  but	  at	  the	  same	  time	  it	  has	  the	  potential	  to	  stimulate	  AC2	  activity	  and	  increase	  production	  of	  the	  pro-­‐inflammatory	  cytokine	  IL-­‐6,	  potentially	  worsening	  the	  disease.	  	  Better	  understanding	  of	  cAMP	  signaling	  compartments	  and	  effects	  downstream	  of	  individual	  AC	  isoforms	  could	  lead	  to	  improved	  therapeutic	  strategies	  for	  asthma.	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Figure	  Captions	  
Fig.	  1	  cAMP	  accumulation	  in	  control	  and	  AC	  overexpressing	  BSMC.	  	  cAMP	  EIA’s	  were	  used	  to	  measure	  cAMP	  following	  10	  min	  exposure	  to	  1	  µM	  Fsk	  or	  vehicle	  in	  the	  presence	  of	  broad-­‐spectrum	  PDE	  inhibitor	  IBMX.	  mean	  ±	  SEM,	  n=3.	  *	  indicates	  p<.05	  compared	  to	  basal.	  
Fig.	  2	  	  a:	  Fsk-­‐induced	  gene	  regulation	  in	  AC	  overexpressing	  BSMC	  compared	  to	  control	  BSMC.	  	  RT2	  q	  PCR	  arrays	  (SA	  Biosciences)	  were	  used	  to	  measure	  mRNA	  levels	  following	  24	  h	  treatment	  with	  1μM	  Fsk.	  	  	  mRNA	  levels	  of	  AC	  overexpressing,	  Fsk-­‐treated	  cells	  are	  expressed	  as	  fold	  change	  with	  respect	  to	  lacZ	  (control),	  Fsk-­‐	  treated.	  	  Amphiregulin	  (AREG),	  Secretogranin	  II	  (SCG2),	  Cyclin	  D1	  (CCND1),	  Interleukin	  6	  (IL-­‐6),	  Somatostatin	  (SST).	  	  	  Data	  are	  presented	  as	  fold	  change	  over	  lacZ,	  mean	  ±	  SEM,	  n=3.	  	  b:	  IL-­‐6	  protein	  production	  in	  AC2	  or	  AC6	  overexpressing	  BSMC.	  	  IL-­‐6	  protein	  in	  cell	  culture	  media	  was	  measured	  by	  ELISA	  following	  24	  h	  treatment	  with	  1	  µM	  of	  the	  indicated	  drug.	  	  Data	  are	  presented	  as	  %	  change	  with	  respect	  to	  lacZ,	  mean	  ±	  SEM,	  n=3.	  	  *	  indicates	  p<.05	  compared	  to	  lacZ	  	  
Fig.	  3	  	  a:	  IL-­‐6	  protein	  production	  in	  response	  to	  Gαs-­‐coupled	  receptor	  agonists.	  	  BSMC	  were	  treated	  with	  the	  indicated	  drug	  for	  24	  h,	  and	  IL-­‐6	  secreted	  into	  culture	  media	  was	  measured	  by	  ELISA.	  	  1µM	  Fsk,	  AVP,	  CGRP,	  glucagon,	  PGD2,	  substance	  P;	  10	  µM	  ATPƔS, 
BRL 37344, NECA. cAMP measured by EIA. b: cAMP	  production	  in	  response	  to	  Gαs	  –coupled	  receptor	  agonists.	  	  BSMC	  were	  pretreated	  with	  0.2	  mM	  IBMX	  prior	  to	  10	  min	  agonist	  exposure:	  	  1µM	  Fsk,	  AVP,	  CGRP,	  glucagon,	  PGD2,	  substance	  P;	  or	  10	  µM	  ATPƔS, 
BRL 37344, NECA. cAMP was measured by EIA. Dashed line represents basal level.  Mean ± 
SEM, n=3-4.  * indicates p<.05 compared to vehicle 
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Fig.	  4	  	  cAMP	  and	  IL-­‐6	  production	  in	  BSMC	  by	  GPCR	  agonists	  alone	  or	  with	  concurrent	  Fsk	  treatment.	  a:	  Cells	  were	  treated	  with	  0.1	  µM	  of	  the	  indicated	  drug	  with	  or	  without	  concurrent	  treatment	  with	  0.1	  µM	  Fsk	  for	  10	  min	  in	  the	  presence	  of	  0.2	  mM	  IBMX.	  	  cAMP	  was	  measured	  by	  EIA..	  	  b:	  Cells	  were	  treated	  with	  0.1	  µM	  of	  the	  indicated	  drug	  with	  or	  without	  concurrent	  treatment	  with	  0.1	  µM	  Fsk.	  	  IL-­‐6	  in	  culture	  media	  was	  measured	  by	  ELISA	  following	  24	  h	  drug	  treatment.	  Mean ± SEM, n=3	  *	  indicates	  p<.05	  compared	  to	  single	  drug	  	  
Fig.	  5	  	  IL-­‐6	  protein	  production	  in	  response	  to	  non-­‐selective,	  Epac	  selective,	  or	  PKA	  selective	  cAMP	  analogs.	  	  BSMC	  were	  treated	  with	  the	  indicated	  concentration	  of	  either	  8-­‐Br-­‐cAMP	  (non-­‐selective),	  8-­‐CPT-­‐2Me-­‐cAMP	  (Epac	  selective),	  or	  6-­‐Bnz-­‐cAMP	  (PKA	  selective)	  for	  24	  h	  and	  IL-­‐6	  in	  culture	  supernatant	  was	  measured	  by	  ELISA.	  Dashed line represents vehicle.  Mean	  ±	  SEM,	  n=3-­‐4	  *	  indicates	  p<.05	  compared	  to	  vehicle	  	  
Fig.	  6	  Fsk-­‐induced	  IL-­‐6	  production	  with	  inhibition	  of	  PKC	  (GF	  109203X),	  p38	  MAPK	  (SB	  202190)	  or	  PI3K	  (wortmanin).	  BSMC	  were	  pretreated	  with	  10	  µM	  of	  the	  indicated	  inhibitor	  for	  1	  h	  prior	  to	  addition	  of	  1	  µM	  Fsk.	  	  RNA	  was	  isolated	  after	  1	  h	  Fsk	  treatment	  and	  measured	  by	  qRT-­‐PCR.	  	  	  Data	  presented	  as	  fold	  over	  vehicle,	  mean	  ±	  SEM,	  n=3	  	  
Fig.	  7	  	  Fsk-­‐induced	  promoter	  activation	  of	  IL-­‐6	  promoter	  mutants.	  	  IL-­‐6	  promoter	  activity	  was	  measured	  by	  luciferase	  assay	  in	  BSMC	  that	  were	  transfected	  with	  1168	  bp	  wild	  type	  or	  mutated	  human	  IL-­‐6	  promoters	  driving	  expression	  of	  luciferase.	  	  Luciferase	  activity	  in	  cell	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lysate	  was	  measured	  following	  6	  h	  treatment	  with	  1	  µM	  Fsk.	  	  Data	  is	  presented	  as	  fold	  over	  the	  basal	  wild-­‐type	  promoter	  activity,	  mean	  ±	  SEM,	  n=11.	  *	  indicates	  p<0.05	  compared	  to	  Fsk	  wild-­‐type	  promoter	  	  	  
